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Summary
Background Early detection and treatment of melanoma is important for optimal
clinical outcome, leading to biopsy of pigmented lesions deemed suspicious for
the disease. The vast majority of such lesions are benign. Thus, a more objective
and accurate means for detection of melanoma is needed to identify lesions for
excision.
Objectives To provide proof-of-principle that epidermal genetic information retrie-
val (EGIR ; DermTech International, La Jolla, CA, U.S.A.), a method that non-
invasively samples cells from stratum corneum by means of adhesive tape
stripping, can be used to discern melanomas from naevi.
Methods Skin overlying pigmented lesions clinically suspicious for melanoma was
harvested using EGIR. RNA isolated from the tapes was ampliﬁed and gene
expression proﬁled. All lesions were removed for histopathological evaluation.
Results Supervised analysis of the microarray data identiﬁed 312 genes differen-
tially expressed between melanomas, naevi and normal skin specimens
(P <0 Æ001, false discovery rate q <0 Æ05). Surprisingly, many of these genes are
known to have a role in melanocyte development and physiology, melanoma,
cancer, and cell growth control. Subsequent class prediction modelling of a train-
ing dataset, consisting of 37 melanomas and 37 naevi, discovered a 17-gene
classiﬁer that discriminates these skin lesions. Upon testing with an independent
dataset, this classiﬁer discerned in situ and invasive melanomas from naevi with
100% sensitivity and 88% speciﬁcity, with an area under the curve for the recei-
ver operating characteristic of 0Æ955.
Conclusions These results demonstrate that EGIR-harvested specimens can be used
to detect melanoma accurately by means of a 17-gene genomic biomarker.
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decades, leading to a doubling of the incidence rate over the
last 10–20 years.
1,2 The invasive form of the disease is already
the seventh most common serious cancer in the U.S.A. with a
lifetime risk of one in 41 in men and one in 61 in women.
Once melanoma has disseminated, the patient’s prognosis is
dismal.
3–5 Most deaths from melanoma could be prevented,
however, if the disease were detected and excised at an early
stage, while still conﬁned to the skin.
4 For example, in situ
melanoma, the earliest skin stage, has a nearly 100% cure rate
when adequately excised. Once melanoma has progressed
locally, especially if it has invaded to a depth of 4 mm or
more, the 10-year survival rate is < 50% because it has already
metastasized before the skin lesion was excised. This makes
the early detection of melanoma critical to patient survival.
Current clinical detection of melanoma relies upon visual
cues, including the ‘ABCDE’ criteria for pigmented naevi, and
results of optical imaging techniques like dermoscopy and
confocal microscopy. Due to the diverse morphologies of pig-
mented lesions, early diagnosis of this tumour can be quite
challenging.
4,6 The occurrence of atypical naevi, precancerous
lesions that can mimic the visual presentation of melanoma
but do not have the histopathological features of this cancer,
is a major confounder to the accurate clinical diagnosis of
melanoma. Studies have shown that clinicians are only able to
determine whether a suspicious pigmented lesion is melanoma
or not with 54–90% sensitivity.
6–8 Clinical expertise was
found to be a key determinant of melanoma diagnostic accur-
acy.
8 Using the benign-to-malignant ratio as an endpoint,
researchers in Australia found that general practitioners bi-
opsied approximately 30 benign pigmented lesions for every
melanoma, while dermatologists biopsied more than 12
pigmented lesions for every melanoma they diagnosed.
9 Taken
together, health care professionals biopsy many pigmented
lesions to detect a melanoma, and may also leave some
melanomas undetected at their early stages.
Techniques to improve the clinical diagnosis of suspicious
pigmented skin lesions are based on enhanced imaging meth-
ods such as dermoscopy and confocal microscopy. Dermo-
scopy has been shown to improve the sensitivity of melanoma
detection by 10–27%;
10,11 however, some early melanomas
are missed by this technique.
12 Other detection strategies
include sequential digital epiluminescence microscopy, reﬂec-
tance confocal microscopy, automated instrumentation for
image analysis, MelaFind  (Mela Sciences, Irvington, NY,
U.S.A.), and the comparison of serial body photographs, e.g.
of atypical naevi, taken at frequent intervals.
13–17 Reﬂectance
confocal microscopy, arguably the more accurate of the confo-
cal techniques, does not reach a sensitivity of 100%.
18
Although digital epiluminescence microscopy has been shown
to improve the sensitivity of melanoma detection signiﬁcantly,
in particular for thin lesions, it has a speciﬁcity of < 20%.
14
The current gold standard for diagnosing melanoma is
histopathological examination of the excised tissue. This
necessitates biopsy of the lesion, an invasive, time- and
resources-consuming procedure that can be impractical,
especially in those patients who have many dysplastic naevi.
Moreover, even histopathology has its limitations. Due to its
subjective nature, discordant readings between expert dermato-
pathologists are reported to occur in 10–35% of potential
cases of melanoma.
19,20
Epidermal genetic information retrieval (EGIR ; DermTech
International, La Jolla, CA, U.S.A.) uses a custom adhesive ﬁlm
to sample RNA from stratum corneum noninvasively. RNA
recovered from the surface of the skin by EGIR has been
quantiﬁed using ribonuclease protection assay, quantitative
real-time reverse transcription–polymerase chain reaction
(qRT-PCR) and DNA microarray analysis to differentiate
irritant from allergic skin reactions and by qRT-PCR to assess
changes in gene expression in psoriatic skin lesions in
response to biotherapy.
21–23 These studies showed the feasibil-
ity of using EGIR-harvested RNA to assess differences in
dermatopathology. In the current study, we sought to exploit
this technology to determine whether the expression proﬁle of
RNA in stratum corneum of normal skin differs from that
overlying a naevus or a malignant melanoma. We report here
that analysis of such EGIR specimens has identiﬁed some 312
genes that differentiate normal skin and naevi from melano-
mas, many of which are relevant to the underlying pathology.
Furthermore, we have used this EGIR-based strategy to
develop a 17-gene classiﬁer that detects both in situ and inva-
sive melanoma with high accuracy.
Materials and methods
Patients and clinical protocols
The study protocols were reviewed and approved by the vari-
ous Institutional Review Boards. Study subjects gave written
informed consent prior to participation and the study was
conducted according to the Declaration of Helsinki principles.
All study subjects were 18 years or older and had a pigmented
lesion 4 mm or greater in diameter that required biopsy due
to suspicion for melanoma (Table 1). Study exclusion criteria
included application of topical medications to the lesion or
use of systemic steroids within 30 days of tape stripping; pres-
ence of a generalized skin disorder such as psoriasis, a photo-
sensitivity disorder, or eczema; known allergy to tape or latex;
use of sunscreen or topical moisturizer within 24 h of tape
stripping; and lesions with clinically overt bleeding, ulceration
or serous exudation. After informed consent, the suspicious
pigmented lesion was taped stripped, as previously
described,
23 and then biopsied as per standard of care. If a
lesion was smaller in size than the 17-mm diameter adhesive
tape disc, the outer edge of the lesion was demarcated on the
tape with indelible ink. A tape-stripped specimen was used in
the study only after the histopathological diagnosis of the
biopsied tissue was reviewed at the primary site and
conﬁrmed by the central dermatopathology reviewer. As a
control, each subject’s normal appearing skin was also sam-
pled by tape stripping. Eighty-two per cent of these control
specimens were garnered from the mastoid process, with the
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minimum distance of 15 cm from the suspicious lesion.
Materials and reagents
The EGIR tape kit contains four small circular adhesive discs,
each 17 mm in diameter, with a polyurethane backing. The
tape was purchased from Adhesives Research (Glen Rock, PA,
U.S.A.) and fabricated into discs with a polyurethane backing
by Diagnostic Laminations Engineering (Oceanside, CA,
U.S.A.). Universal human reference RNA was purchased from
Stratagene (San Diego, CA, U.S.A.). Reverse transcriptase, Taq-
man Universal Master Mix, which included all buffers and
enzymes necessary for the ampliﬁcation and ﬂuorescent detec-
tion of b-actin cDNA, was purchased from Applied Biosystems
(Foster City, CA, U.S.A.). MELT total nucleic acid isolation sys-
tem was purchased from Ambion (Austin, TX, U.S.A.). Gene-
Chip human genome U133 plus 2.0 arrays were purchased
from Affymetrix (Santa Clara, CA, U.S.A.).
RNA isolation and quantiﬁcation
All tape strips were processed in the laboratory at DermTech
International. The RNA was extracted from tapes by means of
MELT and quantiﬁed by TaqMan qRT-PCR for b-actin mRNA
expression level, as per Wong et al.
22 RNA quality was assessed
by microﬂuidic electrophoretic analysis using an Experion
Automated Electrophoresis Station (BioRad, Inc., Hercules, CA,
U.S.A.).
RNA ampliﬁcation and array hybridization
RNA harvested from the EGIR tape strips was ampliﬁed using
the Ovation Pico RNA Ampliﬁcation System (NuGEN Technol-
ogies, Inc., San Carlos, CA, U.S.A.) and hybridized with
Affymetrix human genome U133 plus 2.0 GeneChip, accord-
ing to standard manufacturer protocols.
Gene expression analysis
The image ﬁles from scanning the Affymetrix GeneChips with
the Affymetrix series 3000 scanner were converted to CEL-for-
mat ﬁles using the Affymetrix GeneChip Operating Software
version 1.4. Normalization of GeneChip CEL ﬁles was carried
out using the GCRMA software from Bioconductor (http://
www.bioconductor.org). After ﬁltering out for background
and low expressed genes (level < 100 for a gene target across
all samples), data were imported into GeneSpring (Agilent,
Santa Clara, CA, U.S.A.). A supervised analysis was performed
to identify genes differentially expressed between pigmented
lesions (both melanoma and naevi) (biopsy proven) and
control, nonlesional skin specimens. This was performed by
ANOVA with multiple testing correction using the Westfall and
Young permutation method
24 [P <0 Æ001, false discovery rate
(FDR) q <0 Æ05].
Cluster analysis was performed according to Eisen et al.
25
Data were ﬁrst log2 transformed and then median centred
for genes and samples. The resulting normalized data were
further analysed by the self-organizing map algorithm
26 and
then clustered with Spearman rank correlation similarity
metrics.
To develop a melanoma detection classiﬁer, only the Gene-
Chip data from melanomas and naevi were used. These were
randomly divided into a training set used for multigene classi-
ﬁer selection and a test set for evaluating the performance of
the resultant classiﬁer. Differentially expressed genes were
identiﬁed by unpaired t-test and multiple testing correction
24
(P <0 Æ05, q <0 Æ05) from a training set of 37 melanomas
and 37 naevi. This group of genes was then mined by stochas-
tic gradient boosting, as developed by Friedman
27,28 (available
for use as TreeNet
 ; Salford Systems, San Diego, CA, U.S.A.)
to develop a class prediction model. The resultant multigene
classiﬁer was validated with an independent test dataset
composed of 39 melanomas and 89 naevi.
Gene ontology and pathway analysis was performed with
Ingenuity Pathway Analysis (IPA) system software version 8.5
(Ingenuity Systems, Inc., Redwood City, CA, U.S.A.). Genes
with their corresponding identiﬁers and fold change values
were uploaded for interrogation. After analysis, signiﬁcance of
the biological functions and the canonical pathways was tested
by the Fisher’s exact test P-value to determine the probability
that each biological⁄canonical pathway assigned to the dataset
is due to chance alone.
Table 1 Summary of patient information
Melanoma
(n = 76)
Naevus
(n = 126)
Age (years), mean (range) 60Æ5 (26–95) 45Æ3 (19–79)
Female ⁄male 27 ⁄49 58 ⁄68
Anatomical location
Scalp 8 2
Face 13 3
Neck 3 2
Shoulder 14 26
Trunk 12 74
Upper limb 15 10
Lower limb and hip 11 9
Superﬁcial spreading melanoma
In situ 25
Invasive 40
Lentigo maligna melanoma
In situ 5
Invasive 5
Nodular melanoma 1
Benign naevi 51
Atypical naevi 75
Tumour stage
Tis 31
T1 35
T2 8
T3 1
T4 1
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Use of epidermal genetic information retrieval-harvested
RNA to identify genes differentially expressed between
melanoma, naevi and normal skin
In this study, we sought to address whether the EGIR method
can be used to discern between melanoma, naevi and normal
skin. We harvested 29 melanomas (in situ and invasive), 68
naevi (benign and atypical) and 15 normal skin specimens
from which RNA was isolated, ampliﬁed and proﬁled on the
Affymetrix U133 plus 2.0 GeneChip. ANOVA analysis
(P <0 Æ001, Westfall and Young permutation multiple testing
correction,
24 FDR q <0 Æ05) of the resulting microarray data
identiﬁed 312 differentially expressed genes (the annotated list
of genes is provided in Table S1; see Supporting Information).
Hierarchical clustering analysis of these 312 genes showed
two major branches in the heat map (Fig. 1). The branch on
the left side of the heat map contained all 29 melanomas and
13 of the naevi and was clearly separated from the right
branch that contained the bulk of the naevi as well as all of
the normal skin specimens. Most of the 13 naevi that grouped
together with melanomas were Clark (also known as ‘dysplas-
tic’) naevi with mild to severe cytological atypia, and as such
bear some morphological resemblance to melanoma. Of note
is that normal skin specimens could not be separated from
naevi based on the expression of these 312 genes, suggesting
that the RNA in the stratum corneum over these lesions is
similar. Most of the naevi that grouped together with normal
skin were nondysplastic, compound, intradermal or junctional
naevi. Taken together, these ﬁndings demonstrate that expres-
sion proﬁling of EGIR-harvested RNA from stratum corneum
can be used to identify genes differentially expressed between
melanoma, naevi and normal skin.
Biological functions of the 312 genes related to
melanoma
The biological functions and molecular networks of the 312
genes were assessed by IPA and, interestingly, genes upregulat-
ed in the heat map cluster containing melanoma were found
to play a role in melanocyte development and pigmentation
signalling as well as skin development, cellular development
and cancer (Table 2). Some of the genes upregulated in
these EGIR-harvested stratum corneum specimens overlying
melanoma are shown in Figure 2 including KIT, tyrosinase
(TYR), tyrosinase-related protein 1 (TYRP1), dopachrome tau-
tomerase (DCT), SOX10 and PAX3 – all of which are involved
in melanocyte development and pigmentation. In addition,
other genes known to be expressed in melanocytes, including
MLANA, SILV, EDNRB and melanophilin, were also detected in
these EGIR specimens overlying melanoma. Some of the genes
upregulated in the heat map cluster containing naevi and nor-
mal skin are involved in cellular growth and proliferation,
embryonic development, and skeletal and muscular system
development and function. These ﬁndings support the hypoth-
esis that the EGIR method can be used to distinguish mela-
noma from naevi and normal skin. Further, these observations
suggest that the gene expression proﬁle of mRNA found in the
stratum corneum overlying a pigmented lesion is altered,
either directly or indirectly, by the presence of melanoma.
Identiﬁcation of a 17-gene classiﬁer to distinguish
melanoma from naevi
Having demonstrated that EGIR tape-stripped specimens can
be used to detect melanoma, we next asked whether we could
develop an approach to predict the risk that a pigmented
lesion contains a melanoma. Our strategy was to develop a
Fig 1. Hierarchical clustering analysis of
differentially expressed genes among
melanomas, naevi and normal skin. These 312
genes determined from microarray analysis of
epidermal genetic information retrieval
specimens differentiate melanoma from
atypical naevi and normal skin (P <0 Æ001,
false discovery rate q <0 Æ05).
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noma from a naevus using the expression proﬁles of known
samples – a training set consisting of melanoma and naevi –
and then use the resultant multigene classiﬁer to assess an
independent group of samples – a test set containing melano-
mas and naevi (details of the analytical schema are provided
in Data S1; see Supporting Information).
Accordingly, we employed EGIR to obtain RNA from 202
tape-stripped melanomas and naevi (Table 1), each of which
was proﬁled on the Affymetrix human U133 plus 2.0 Gene-
Chip. The resulting microarray data were randomly divided
into training and test datasets. The training set consisted of
data from 37 melanomas, including in situ (14) and invasive
superﬁcial spreading melanomas (19), lentigo maligna (3)
and lentigo maligna melanoma (1), and 37 naevi (both dys-
plastic and nondysplastic), while the test set contained data
from 39 melanomas including in situ (11) and invasive super-
ﬁcial spreading melanomas (21), lentigo maligna (2), lentigo
maligna melanoma (4) and nodular melanoma (1), and 89
naevi (both dysplastic and nondysplastic). The training data-
set yielded some 422 genes differentially expressed between
melanomas and naevi, as determined by Student’s t-test with
multiple testing correction (P <0 Æ05, FDR q <0 Æ05) (the
annotated list of genes is provided in Table S2; see Support-
ing Information). The group of 422 differentially expressed
genes was then subjected to class prediction modelling to
identify a multigene classiﬁer capable of discerning a mela-
noma from a naevus after which its performance was
assessed by the independent, test set data. This was accom-
plished by stochastic gradient boosting analysis, using the
TreeNet data mining algorithm, which permits selection and
performance testing of a multigene classiﬁer. Unlike classical
modelling techniques, the stochastic gradient boosting algo-
rithm utilizes very ﬂexible structural assumptions and is capa-
ble of accommodating multiple sets of genes associated with
different classiﬁcation outcomes in a true multivariate fash-
ion. We found that a classiﬁer from the training set contain-
ing 168 of the 422 genes was sufﬁcient to correctly identify
all 37 melanomas and 35 of 37 naevi (the annotated list of
the 168 genes is provided in Table S3; see Supporting Infor-
mation). Thus, the sensitivity and speciﬁcity of detecting
melanoma in the training dataset was 100% and 95%,
respectively. The performance of this class prediction model
was evaluated with an independent test dataset of 39 mela-
nomas and 89 naevi. All 39 of the melanomas in the test
dataset were accurately identiﬁed and 78 of the 89 naevi
were called correctly by the 168-gene classiﬁer, indicative of
100% sensitivity and 88% speciﬁcity. The pathology of the
false-positive specimens was variable and included dysplastic
naevus (n = 7), compound naevus (n = 5) and junctional
naevus (n = 1).
Further TreeNet modelling revealed that the classiﬁer could
be reduced to a set of 17 of 168 genes that remained 100%
sensitive and 88% speciﬁc upon testing (Tables 3 and 4; more
complete annotation on these 17 genes is provided in
Table S4; see Supporting Information). Furthermore, receiver
operating characteristic (ROC) curve analysis of the application
of the 17-gene classiﬁer to the test dataset resulted in an area
Table 2 Top biological functions of 312 differentially expressed genes among melanoma, naevi and normal skin controls
No. of
molecules Ratio P-value
Molecular and cellular functions
Amino acid metabolism 5 2Æ73 · 10
)8–1Æ40 · 10
)2
Small molecule biochemistry 12 2Æ73 · 10
)8–1Æ40 · 10
)2
Cellular development 67 5Æ78 · 10
)8–1Æ40 · 10
)2
Cellular growth and proliferation 66 1Æ25 · 10
)6–1Æ40 · 10
)2
Cell death 63 1Æ34 · 10
)6–1Æ40 · 10
)2
Physiological system development and function
Hair and skin development and function 20 2Æ73 · 10
)8–1Æ40 · 10
)2
Embryonic development 30 4Æ99 · 10
)6–1Æ40 · 10
)2
Renal and urological system development and function 13 6Æ37 · 10
)5–1Æ40 · 10
)2
Organ development 37 7Æ43 · 10
)5–1Æ40 · 10
)2
Cardiovascular system development and function 35 1Æ53 · 10
)4–1Æ40 · 10
)2
Diseases and disorders
Cancer 83 2Æ32 · 10
)9–1Æ40 · 10
)2
Gastrointestinal disease 33 1Æ37 · 10
)6–1Æ40 · 10
)2
Skeletal and muscular disorders 74 3Æ74 · 10
)6–1Æ40 · 10
)2
Infectious disease 33 5Æ42 · 10
)6–9Æ34 · 10
)3
Respiratory disease 17 5Æ42 · 10
)6–2Æ44 · 10
)3
Canonical pathways
Melanocyte development and pigmentation signalling 7 ⁄88 (0Æ08) 1Æ35 · 10
)4
Factors producing cardiogenesis in vertebrates 6 ⁄89 (0Æ067) 9Æ33 · 10
)4
Axonal guidance signalling 12 ⁄403 (0Æ03) 4Æ39 · 10
)3
Human embryonic stem cell pluripotency 6 ⁄148 (0Æ041) 6Æ46 · 10
)3
Wnt ⁄b-catenin signalling 7 ⁄168 (0Æ042) 6Æ97 · 10
)3
  2011 The Authors
BJD   2011 British Association of Dermatologists 2011 164, pp797–806
Genomic detection of melanoma, W. Wachsman et al. 801under the curve (AUC) of 0Æ955, indicating that it is extremely
accurate for melanoma detection. We used the 17-gene
classiﬁer to evaluate several types of EGIR-harvested additional
control lesions, including 73 normal, nonlesional skin samples
from both healthy subjects (n = 53) and patients with mela-
noma (n = 19) or basal cell carcinoma (n = 1), 18 pigmented
basal cell carcinomas, and 22 solar lentigines. The assay for
melanoma of these specimens was negative for all of the nonle-
sional skin specimens and the solar lentigines, as well as 17 of
the 18 basal cell carcinomas (data not shown). These ﬁndings
provide further support for the speciﬁcity of the 17-gene classi-
ﬁer to detect melanoma speciﬁcally.
Fig 2. Ingenuity Pathway Analysis of epidermal genetic information retrieval-harvested melanoma specimens identiﬁes overexpressed genes
involved in melanocyte development and pigmentation. Melanocyte development and pigmentation is primarily regulated by microphthalmia-
associated transcription factor (MITF), which is controlled mainly through the melanocyte-stimulating hormone (MSH) signalling pathway that
includes adenylate cyclase 2 (ADCY2), sex determining region Y-box 10 (SOX10) and paired box 3 (PAX3) as well as the v-kit Hardy–Zuckerman
4 feline sarcoma viral oncogene homolog (Kit) signalling pathway. Tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1) and dopachrome
tautomerase (DCT) are activated by MITF and are also involved in skin pigmentation.
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ogy readings on the naevi deemed to be melanomas, or falsely
positive, by the 17-gene classiﬁer. Therefore, each of the 13
false-positive specimens was serially sectioned and re-reviewed
by both primary and central dermatopathologists. In so doing,
it was determined by both pathologists that one of 13 false-
positive naevi actually harboured an invasive superﬁcial
spreading melanoma (the specimen denoted by an arrow in
Fig. 3) (photomicrographs are provided in Fig. S1; see Sup-
porting Information).
Biological functions of the 17-gene classiﬁer
Among the 17-gene classiﬁer (Table 4), nine genes (ACTN4,
CMIP, CNN2, TTC3, VDAC1, NAMPT, RPL21, RPS15 and
RPL18) are located in the cytoplasm, ﬁve genes (EDNRB,
GPM6B, TMEM80, KIT and TRIB2) are in the plasma mem-
brane, PRAME is in the nucleus and two genes (BC020163
and MGC40222) are unknown. KIT, a receptor tyrosine
kinase, and EDNRB, a G-protein coupled receptor, are critical
regulators in melanocyte development and pigmentation sig-
nalling, hair and skin development, and melanoma progres-
sion (Fig. 2). The gene encoding preferentially expressed
antigen in melanoma (PRAME) is not only involved in mela-
noma progression but is also implicated in ovarian cancer,
neoplasia and breast cancer.
29,30
The biological functions of genes in the 17-gene classiﬁer
analysed by IPA were primarily involved in cell death
(ACTN4, CNN2, EDNRB, KIT, NAMPT, PRAME, TRIB2 and
VDAC1), cellular development (EDNRB, KIT, PRAME, TRIB2,
TTC3, CNN2, ACTN4, VDAC1 and NAMPT), hair and skin
development (EDNRB and KIT), cancer (EDNRB, KIT, TTC3,
NAMPT, PRAME and RPS15) and neurological disease
(EDNRB, KIT, NAMPT, RPL21 and TTC3). In addition, EDNRB
and KIT were used as clinical drug targets for treatment of
metastatic melanoma and so was NAMPT in gastric cancer.
31–33
These results demonstrate that most of the genes in this classi-
ﬁer, which distinguishes melanoma from naevi, are involved in
melanoma and cancer.
Discussion
In this study we have demonstrated that EGIR, noninvasive
tape stripping of stratum corneum, can be used to detect mel-
anoma. We have identiﬁed 312 genes that are differentially
expressed between melanoma, naevi and normal skin. This is
the ﬁrst demonstration that EGIR, a method that samples
material from stratum corneum, is capable of detecting signals
from cells that typically exist in the basal layer of the epidermis.
In addition, EGIR technology was also able to discriminate
melanomas from naevi, including dysplastic naevi, with high
sensitivity and speciﬁcity using 422 differentially expressed
genes. Reducing the number of genes to 17, a more practical
number that could be tested clinically, still resulted in a classi-
ﬁer with 100% sensitivity and 88% speciﬁcity for the detection
of in situ and invasive superﬁcial spreading melanoma, lentigo
maligna and lentigo maligna melanoma with an ROC AUC of
better than 0Æ95. This 17-gene classiﬁer also discriminates
Table 3 A 17-gene melanoma classiﬁer accurately discriminates
melanoma from naevi
Histopathological
diagnosis
Training set Test set
Melanoma Naevus Melanoma Naevus
Melanoma 37 0 39 0
Naevus 2 35 11 78
Table 4 List of the 17-gene melanoma
classiﬁer Gene name GenBank Description
ACTN4 U48734 Actinin, alpha 4
BC020163 AW342078 Homo sapiens, clone IMAGE:4346533, mRNA
CMIP AI819630 c-Maf-inducing protein
CNN2 NM_004368 Calponin 2
EDNRB M74921 Endothelin receptor type B
GPM6B AW148844 Glycoprotein M6B
KIT NM_000222 v-kit Hardy–Zuckerman 4 feline sarcoma viral
oncogene homolog
MGC40222 N44676 Hypothetical protein MGC40222
NAMPT NM_005746 Nicotimamide phosphoribosyltransferase
PRAME NM_006115 Preferentially expressed antigen in melanoma
RPL18 AV738806 Ribosomal protein L18
RPL21 AL356414 Ribosomal protein L21
RPS15 NM_001018 Ribosomal protein S15
TMEM80 AI739035 Transmembrane protein 80
TRIB2 NM_021643 Tribbles homolog 2 (Drosophila)
TTC3 NM_003316 Tetratricopeptide repeat domain 3
VDAC1 AL515918 Voltage-dependent anion channel 1
  2011 The Authors
BJD   2011 British Association of Dermatologists 2011 164, pp797–806
Genomic detection of melanoma, W. Wachsman et al. 803melanoma from basal cell carcinoma, solar lentigo and normal
skin.
The 17-gene classiﬁer falsely identiﬁed 13 naevi as mela-
noma, raising the question as to why these were misclassiﬁed.
One possibility is due to a sampling error by histopathological
examination of a limited number of sections from the biopsied
specimen. This is clearly the case for one of the specimens
(denoted by an arrow in Fig. 3), which when serial sectioned
and re-reviewed was found to harbour a melanoma. This had
been missed during the initial histopathological reading due to
the fact that serial sectioning of the biopsied lesion is not rou-
tinely performed per standard of care. Another possibility is that
EGIR-based genomic assay can detect molecular changes prior
to the development of morphological abnormalities in mela-
noma cells. A third possibility is that these false-positive naevi
exhibited pagetoid spread of melanocytes. After re-reviewing
the tissue biopsy specimens we could ﬁnd little, if any, evidence
of pagetoid spreading in these false-positive naevi. If these
results can be conﬁrmed, it would suggest that the EGIR-based
genomic assay may be a more sensitive means to detect mela-
noma than the standard histopathological review.
Tape stripping removes mainly the stratum corneum, the
layer of the skin that does not contain nuclei. The pigment-
producing cell, the melanocyte, however, resides in the basal
cell layer of the epidermis. Thus, it is surprising that one can
isolate mRNA, indicative of this neoplasm, from the skin’s
horny layer. Several observations may explain this ﬁnding. It
is known that the distal portion of the melanocyte’s dendritic
processes are actively phagocytosed by keratinocytes and the
melanin contained in these processes is then dispersed
throughout the keratinocyte layers, eventually arriving in the
stratum corneum.
34 This appears to be the mechanism by
which pigment moves to the upper⁄outermost layers of the
integument from the melanocyte that produces the melanin.
Conceivably, the mRNA synthesized by the melanocyte also
moves upwards in the epidermis during this process. The
keratinocyte may also phagocytose the dendritic processes of
Langerhans cells. This would explain why mRNA indicative of
an allergic reaction, thought to be a function of the Langer-
hans cells resident in the suprabasal cell layer, can also be
found in the stratum corneum.
21 In addition, documentation
of the mRNA indicative of an abnormal skin reaction at the
skin’s surface may be explained by the recent observation that
the dendritic processes of Langerhans cells penetrate through
the tight junctions of the keratinocytes and exit the skin just
beneath the stratum corneum where the RNA could be picked
up by the tape stripping.
35
Another possibility for our ﬁndings is the phenomenon of
cell–cell crosstalk (see below). In this scenario the malignant
melanocyte in the epidermis would activate the keratinocytes
adjacent to it to generate melanocytic mRNAs, and this process
would continue until the abnormal expression of mRNAs
would manifest itself in the uppermost layer of the stratum
granulosum when the nucleus becomes extruded. From there,
the mRNAs indicative of a melanoma could be detected by
tape stripping.
Alternatively, the RNA from malignant melanocytes could
be sampled by EGIR if the malignant cell is present in the stra-
tum corneum or if tape stripping extends well below into the
stratum granulosum. The former is unlikely because it is
thought to be a rare event and therefore not capable of gener-
ating a signal strong enough to overcome the surrounding
noise of corniﬁed keratinocytes. The latter also would not
provide a clear explanation, as histopathological review of
specimens typically did not show that tape stripping resulted
in penetration beyond the stratum corneum layer. However,
it is possible that dendritic processes from the malignant
melanocytes could extend into the stratum corneum that
might be sampled during the process of EGIR.
Recent ﬁndings on the genetics of melanoma have shown
distinct subsets of the disease in which speciﬁc genomic aber-
rations have been associated with histological subtypes of
Fig 3. Hierarchical clustering of melanomas and naevi using the 17-gene classiﬁer. Shown are data from the training set of 37 melanomas and 37
naevi. The specimen denoted by the arrow was called a Clark naevus on initial pathological review, but was deemed a melanoma by the 17-gene
classiﬁer. The presence of invasive melanoma was detected in this biopsy by both the primary and central dermatopathologists upon re-review of
the serially sectioned specimen.
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amount of sun exposure.
36–38 Strikingly, our ﬁndings indicate
that a core of genes is expressed in both in situ and invasive
melanoma and in lesions of various histologies, including
those associated (i.e. lentigo maligna) or not associated (i.e.
superﬁcial spreading) with chronic sun exposure. Among 142
upregulated genes in melanoma, many are known to be
expressed speciﬁcally in melanocytes, including KIT, Melan-A,
TYR, TRPM1, EDNRB, DCT, SOX10 and SILV (Fig. 2). In
addition, the biological functions of these upregulated genes
are also involved in melanocyte biology, skin⁄hair pigmenta-
tion, cellular growth⁄proliferation and cancer (Fig. 2,
Table 2), thereby suggesting that many are biologically rele-
vant to processes occurring within the underlying epidermal
tissue. Thus, it is possible that these genes represent a com-
mon thread of genetic progression for melanoma develop-
ment that occurs at the earliest stage of disease – and may
provide a target or group of targets for therapeutic interven-
tion. Lastly, the histopathological differentiation of lentigo
maligna and lentigo maligna melanoma from solar lentigo
can often be extremely difﬁcult. This 17-gene classiﬁer sepa-
rates this form of melanoma from the benign process, pro-
viding a potential tool for the accurate diagnosis of these
difﬁcult pigmented lesions.
Preliminary qRT-PCR results for expression of the 17-gene
classiﬁer from 10 melanomas and 10 naevi showed very simi-
lar results to the data from the GeneChip microarray, with all
10 melanomas and nine of 10 naevi being discerned correctly
(Data S2; see Supporting Information). This preliminary ﬁnd-
ing strongly suggests that the classiﬁer, discovered by micro-
array analyses of EGIR specimens, will translate well on to a
qRT-PCR platform that should be cost-effective for use in the
clinical setting. Should these ﬁndings be recapitulated in an
expanded clinical validation study, such an assay may be sub-
stantially more accurate and certainly more objective than the
visual and optical means currently available for melanoma
detection. Such a test would also permit clinicians to be vastly
more selective in their choice of pigmented skin lesions that
need to be biopsied and further evaluated.
What’s already known about this topic?
• Adhesive tape stripping of skin yields RNA from stratum
corneum that can be assayed for gene expression to
assess allergic and irritant skin reactions and psoriasis.
What does this study add?
• RNA from tape-stripped skin identiﬁed genes present in
stratum corneum that are differentially expressed
between melanoma, naevus and normal skin specimens.
• A 17-gene genomic biomarker was characterized that
accurately discriminates in situ and invasive melanomas
from naevi.
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Supporting Information
Additional Supporting Information may be found in the online
version of the article:
Fig S1. Photomicrographs of a melanoma, not identiﬁed on
initial histopathological evaluation, which was detected by the
17-gene melanoma classiﬁer.
Table S1. Table of 312 differentially expressed genes
between melanomas, naevi and normal skin specimens.
Table S2. Table of 422 differentially expressed genes
between melanomas and naevi.
Table S3. Table of 168 genes identiﬁed by the TreeNet
analysis in the training set.
Table S4. Description of the 17-gene melanoma classiﬁer.
Data S1. Details of strategy for melanoma class prediction
modelling.
Data S2. Assay of melanoma and nonmelanoma specimens
by quantitative real-time reverse transcription–polymerase
chain reaction using the 17-gene classiﬁer recapitulates micro-
array results.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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